New Drugs Added to Knowledgebase

Last week we added 15 new drugs to the knowledgebase:

• Dovitinib a tyrosine kinase inhibitor for the treatment of renal cell carcinoma
• Stenoparib a PARP and Tankyrase inhibitor for the treatment of ovarian cancer
• CLN-081 an epidermal growth factor (EGFR) tyrosine kinase inhibitor (TKI) inhibitor for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor (EGFR) exon 20 insertion mutations
• AT-007 an aldose reductase inhibitor for the treatment of Galactosemia sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 deficiency
• Efanesoctocog alfa a recombinant factor VIII therapy for the treatment of hemophilia A
• Cefepime-taniborbactam a monobactam/beta-lactamasde inhibitor for the treatment of complicated urinary tract infection (UTI)
• CAP-1002 a cardiosphere-derived cell therapy for the treatment of Duchenne Muscular Dystrophy
• Telisotuzumab vedotin (teliso-V) an antibody drug conjugate (ADC) for the treatment of advanced or metastatic EGFR wild-type, nonsquamous non–small cell lung cancer (NSCLC) who have high levels of c-Met overexpression
• Zandelisib a phosphatidylinositol-3-kinase (PI3K) inhibitor for the treatment of follicular lymphoma, marginal zone lymphoma
• Enobosarm a non-steroidal, selective androgen receptor agonist, for the treatment of androgen receptor (AR)–positive, estrogen receptor (ER)–positive, HER2-negative, metastatic breast cancer 
• Futibatinib a tyrosine kinase inhibitor for the treatment of metastatic cholangiocarcinoma harboring FGFR2 gene rearrangements, including gene fusions
• Gedatolisib a PI3K and mTOR inhibitor for the treatment of hormone receptor–positive, HER2-negative metastatic breast cancer who experienced disease progression on CDK4/6 therapy
• Adagrasib a KRAS inhibitor for the treatment of KRASG12C-mutated solid tumors, non-small cell lung cancer (NSCLC)
• MB-207 a gene therapy for the treatment of X-linked severe combined immunodeficiency (SCID-X1)
• CAP-1002 an allogeneic cardiosphere-derived cells therapy of the treatment of Duchenne Muscular Dystrophy

The Prescribe Right Pharmaceutical Pipeline Tracker now allows you to track 980 pipeline and recently approved drugs supported by 2,364 announced and published study results.